Cryopraxis is a Brazilian biotechnology company headquartered in Rio de Janeiro, Brazil, specializing in stem cell therapies and cryopreservation technologies for the treatment of neurodegenerative diseases. Founded in 2005, the company has developed expertise in mesenchymal stem cell (MSC) therapies and has advanced several candidates into clinical development for Parkinson's disease, Alzheimer's disease, and other neurological disorders.
Cryopraxis represents one of the leading cell therapy companies in Latin America, with a focus on leveraging Brazil's robust stem cell research infrastructure and favorable regulatory environment for advanced therapies. The company's mission centers on developing accessible, innovative cell-based treatments for neurodegenerative conditions that currently lack disease-modifying therapies.
| Attribute |
Details |
| Headquarters |
Rio de Janeiro, Brazil |
| Founded |
2005 |
| Focus |
Stem cell therapy, cryopreservation |
| Stage |
Clinical stage |
| Employees |
~80 |
| Ownership |
Private |
| Market |
Brazil, Latin America |
Cryopraxis was founded in 2005 as a spinout from the National Cancer Institute of Brazil (INCA), leveraging over two decades of stem cell research expertise. The company's evolution reflects Brazil's broader growth in the biotechnology sector:
- 2005: Company founded with INCA partnership
- 2010: Established GMP manufacturing facility
- 2015: First IND approval for Parkinson's disease trial
- 2018: Expanded to Alzheimer's and ALS programs
- 2022: Phase 1/2 trial enrollment completed for PD
- 2024: Pipeline advancement and international partnerships
Cryopraxis focuses on three major neurodegenerative indications, each representing significant unmet medical need in Brazil and globally:
Parkinson's disease affects approximately 200,000-250,000 people in Brazil, with prevalence increasing with age. Cryopraxis has an advanced stem cell program for PD that represents the company's most advanced clinical program.
Clinical Program: CPX-001
- Cell type: Mesenchymal stem cells (MSCs) derived from bone marrow
- Dosing: Multiple intravenous infusions
- Trial phase: Phase 1/2 (completed enrollment)
- Primary endpoints: Safety and motor function improvement
Mechanism of Action: MSCs mediate neuroprotection through multiple pathways:
- Trophic factor secretion: GDNF, BDNF, and other neurotrophic factors
- Immunomodulation: Reduction of pro-inflammatory cytokines
- Anti-apoptotic effects: Protection of dopaminergic neurons
- Mitochondrial support: Enhancement of neuronal energy metabolism
Alzheimer's disease represents the leading cause of dementia in Brazil, affecting over 1 million people. Cryopraxis is developing MSC therapies targeting the neuroinflammatory components of AD pathophysiology.
Clinical Program: CPX-002
- Cell type: Allogeneic MSCs from umbilical cord
- Target: Neuroinflammation and synaptic protection
- Approach: Systemic administration to modulate peripheral and CNS immunity
- Status: Phase 1 planned
Rationale: The neuroinflammatory hypothesis of AD suggests that modulation of microglial activation and peripheral immune responses may provide disease-modifying benefits. MSCs can shift microglia from pro-inflammatory to neuroprotective phenotypes.
ALS affects approximately 15,000 people in Brazil, with rapid progression and limited treatment options. Cryopraxis has expanded into ALS based on the immunomodulatory potential of MSCs.
Clinical Program: CPX-003
- Rationale: MSC-mediated immunomodulation may slow disease progression
- Clinical status: Phase 1 completed
- Findings: Safety established, signals of biological activity
Mesenchymal stem cells represent Cryopraxis' core technology platform. These adult stem cells are derived from multiple tissue sources and possess potent immunomodulatory and trophic properties.
| Source |
Advantages |
Applications |
| Bone marrow |
Well-characterized |
Primary program |
| Adipose tissue |
Abundant, minimally invasive |
Backup programs |
| Umbilical cord |
Young cells, immunomodulatory |
AD program |
| Dental pulp |
Easy access |
Research programs |
Cryopraxis operates GMP-compliant manufacturing facilities:
- Cell banking: Master cell banks (MCB) and working cell banks (WCB)
- Quality control: Comprehensive potency assays, sterility testing
- Scale-up: Suspension culture systems for large-scale production
- Cryopreservation: Optimized protocols maintaining cell viability >90%
The company's cryopreservation capabilities represent a key differentiator:
- Vitrification technology: Avoids ice crystal formation
- Optimized protocols: DMSO-free cryoprotectants in development
- Cell banking: Master cell banks for allogenic products
- Logistics: Distribution infrastructure for Brazil and Latin America
- Extended shelf life: Products can be stored for years
- Quality assurance: Batch-to-batch consistency
- Flexibility: On-demand dosing for clinical applications
- Access: Enables distribution to remote locations
| Product |
Indication |
Cell Source |
Stage |
Status |
| CPX-001 |
Parkinson's disease |
Bone marrow MSC |
Phase 1/2 |
Completed enrollment |
| CPX-002 |
Alzheimer's disease |
Umbilical cord MSC |
Phase 1 |
Planning |
| CPX-003 |
ALS |
Bone marrow MSC |
Phase 1 |
Completed |
| CPX-004 |
Multiple sclerosis |
Adipose MSC |
Preclinical |
Research |
Trial design: Multi-center, open-label, dose-escalation study
- Population: Patients with Hoehn-Yahr stage 2-3 Parkinson's disease
- Cohorts: Three dose levels (1x10^6, 2x10^6, 4x10^6 cells/kg)
- Endpoints: UPDRS motor score, quality of life measures
- Follow-up: 12 months primary, 24 months extended observation
Published results:
- Safety established at all dose levels
- Signals of motor improvement in higher dose cohorts
- No serious adverse events related to treatment
- Population: Patients with definite or probable ALS
- Design: Single-dose, safety-focused
- Outcomes: Safety primary, secondary measures of disease progression
MSCs exert therapeutic effects through multiple complementary mechanisms:
- Paracrine signaling: Secretion of neurotrophic factors (GDNF, BDNF, NGF)
- Immunomodulation: Suppression of T-cell proliferation, modulation of macrophages
- Anti-inflammatory: Reduction of TNF-α, IL-1β, IL-6
- Anti-apoptotic: Inhibition of caspase activation in neurons
- Mitochondrial transfer: Restoration of mitochondrial function in damaged cells
- Angiogenesis: Support of vascular repair in the CNS
- Blood-brain barrier modulation: MSCs can transiently open BBB for enhanced CNS delivery
- Allogeneic potential: Off-the-shelf products possible due to immunoprivileged nature
- Safety profile: Low risk of tumor formation or ectopic tissue
- Repeat dosing: Unlike embryonic stem cells, repeat administration is feasible
Cryopraxis operates under Brazil's regulatory framework for cell therapy, which has evolved significantly since 2015:
- ANVISA: Regulatory authority for cell therapy products
- CONITEC: Evaluates incorporation into public healthcare system
- Ethics committees: Required for all clinical trials
The company is pursuing regulatory pathways in:
- Argentina: ANMAT approval
- Colombia: INVIMA registration
- United States: FDA pre-IND consultations
¶ Partnerships and Collaborations
- National Cancer Institute (INCA): Founding research collaboration
- University of Rio de Janeiro (UFRJ): Stem cell biology research
- Federal University of São Paulo (UNIFESP): Neurology expertise
- São Paulo State University (UNESP): MSC manufacturing optimization
- International pharma: Clinical trial partnerships for late-stage development
- Regional distributors: Latin America commercial partnerships
- Technology transfer: Manufacturing partnerships for scale-up
- Ministry of Health: SUS integration discussions
- FINEP: Funding for technology development
- Brazilian Innovation Agency: Support for advanced therapy infrastructure
Brazil represents the largest healthcare market in Latin America, with:
- Population: 215 million people
- Neurodegenerative disease burden: Growing with aging population
- Healthcare spending: Increasing government investment
- Regulatory environment: Supportive of advanced therapies
¶ Competitive Landscape
| Company |
Country |
Technology |
Status |
| Cryopraxis |
Brazil |
MSC therapy |
Phase 1/2 |
| Stemedica |
USA |
MSC therapy |
Phase 2 |
| Hope Biosciences |
USA |
MSC therapy |
Phase 1/2 |
| Cytopeutics |
Australia |
MSC therapy |
Phase 1 |
Cryopraxis differentiates through:
- Brazil-first approach leveraging local regulatory expertise
- Established GMP infrastructure
- Academic hospital partnerships for clinical execution
Cryopraxis has outlined several strategic priorities:
- Complete CPX-001 trial: Finalize Phase 1/2 data analysis
- Advance CPX-002: Initiate Alzheimer's trial enrollment
- International expansion: Pursue FDA and EMA regulatory pathways
- Combination strategies: Explore MSC combinations with small molecules
- Next-generation platforms: iPSC-derived cell therapies